Table 4.
SPM risks at various anatomical sites based on previous surgery and radiotherapy treatments in rectal CA patients.
| Events | Treatment for rectal cancer | p | |||||
|---|---|---|---|---|---|---|---|
| Surgery only | Surgery combined with radiotherapy | ||||||
| Obs | SIR | 95% CI | Obs | SIR | 95% CI | ||
| All sites | 3,253 | 1.13* | 1.1–1.17 | 213 | 1.1 | 0.96–1.26 | 0.782 |
| All sites excluding non-melanoma skin | 3,236 | 1.13* | 1.09–1.17 | 213 | 1.11 | 0.96–1.27 | 0.821 |
| All solid tumors | 2,951 | 1.16* | 1.12–1.21 | 192 | 1.12 | 0.97–1.29 | 0.742 |
| Oral cavity and pharynx | 74 | 1.08 | 0.85–1.36 | 4 | 0.86 | 0.23–2.21 | 0.745 |
| Esophagus | 47 | 1.38* | 1.02–1.84 | 2 | 0.86 | 0.1–3.09 | 0.625 |
| Stomach | 57 | 1.12 | 0.85–1.45 | 2 | 0.58 | 0.07–2.09 | 0.459 |
| Small Intestine | 30 | 2.21* | 1.49–3.16 | 4 | 4.40* | 1.2–11.27 | 0.547 |
| Colon and rectum | 680 | 2.45* | 2.27–2.64 | 33 | 1.74* | 1.2–2.45 | 0.262 |
| Liver | 55 | 1.14 | 0.86–1.49 | 2 | 0.61 | 0.07–2.2 | 0.488 |
| Gallbladder | 7 | 0.93 | 0.37–1.91 | 0 | 0 | 0–7.49 | 0.428 |
| Pancreas | 81 | 0.92 | 0.73–1.15 | 4 | 0.69 | 0.19–1.76 | 0.657 |
| Larynx | 21 | 0.88 | 0.54–1.34 | 0 | 0 | 0–2.2 | 0.151 |
| Lung and bronchus | 504 | 1.13* | 1.03–1.23 | 51 | 1.70* | 1.26–2.23 | 0.085 |
| Bones and joints | 4 | 1.54 | 0.42–3.95 | 2 | 11.48* | 1.39–41.48 | 0.343 |
| Soft tissue including heart | 19 | 1.18 | 0.71–1.85 | 0 | 0 | 0–3.43 | 0.201 |
| Melanoma of the skin | 113 | 0.86 | 0.71–1.03 | 14 | 1.61 | 0.88–2.7 | 0.156 |
| Breast | 239 | 0.86* | 0.75–0.97 | 23 | 1.33 | 0.85–2 | 0.18 |
| Cervix uteri | 9 | 1.03 | 0.47–1.96 | 1 | 1.78 | 0.05–9.93 | 0.747 |
| Corpus uteri | 72 | 1.27 | 0.99–1.6 | 7 | 2.02 | 0.81–4.17 | 0.486 |
| Uterus, NOS | 0 | 0 | 0–2.12 | 0 | 0 | 0–33.98 | 0.999 |
| Ovary | 24 | 0.87 | 0.55–1.29 | 1 | 0.58 | 0.01–3.24 | 0.754 |
| Vagina | 2 | 1.07 | 0.13–3.88 | 1 | 8.65 | 0.22–48.21 | 0.445 |
| Prostate | 459 | 0.86* | 0.78–0.94 | 10 | 0.26* | 0.13–0.48 | <0.001# |
| Urinary bladder | 189 | 1.08 | 0.93–1.25 | 12 | 1.01 | 0.52–1.76 | 0.869 |
| Kidney | 89 | 1 | 0.8–1.23 | 3 | 0.5 | 0.1–1.46 | 0.321 |
| Renal pelvis | 8 | 1.08 | 0.47–2.13 | 2 | 4.06 | 0.49–14.65 | 0.385 |
| Ureter | 4 | 0.84 | 0.23–2.14 | 1 | 3.11 | 0.08–17.35 | 0.508 |
| Eye and orbit | 0 | 0.00* | 0–0.82 | 0 | 0 | 0–12.41 | 0.999 |
| Brain and other nervous system | 25 | 0.86 | 0.56–1.27 | 1 | 0.51 | 0.01–2.87 | 0.678 |
| Thyroid | 47 | 1.34 | 0.98–1.78 | 2 | 0.89 | 0.11–3.2 | 0.677 |
| Lymphoma | 101 | 0.77* | 0.63–0.94 | 9 | 1.04 | 0.47–1.97 | 0.554 |
| Myeloma | 37 | 0.82 | 0.58–1.13 | 3 | 0.98 | 0.2–2.87 | 0.83 |
| Leukemia | 85 | 1.03 | 0.83–1.28 | 4 | 0.73 | 0.2–1.87 | 0.602 |
CA, classical adenocarcinoma; Obs, observed events; SIR, standard incidence ratio; CI, confidence interval;
*
P < 0.05 (compared with general population).
#
P < 0.05. P-values comparing SIRs for rectal CA survivors who received surgery only vs. surgery combined with radiotherapy were calculated using Poisson regression.